TURIN, Italy I October 30, 2024 I Kither Biotech, a clinical-stage biotech company focused on innovative therapies for respiratory diseases, today announced ...

The first Phase 2 study (NCT01425814) of abediterol as a COPD treatment was completed in 2012. It evaluate four single doses of inhaled abediterol at 0.625, 2.5, 5 or 10 micrograms and compared its ...